EMBER THERAPEUTICS, INC.

Ember Therapeutics, Inc. Share Price

Equities

EMBT

US29082W1099

Market Closed - OTC Markets Other stock markets 07:32:31 20/09/2023 pm IST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2019	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
2018	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Chart Ember Therapeutics, Inc.

Duration

Period

Style

Latest news about Ember Therapeutics, Inc.

Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	16/19/16	CI
Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	16/18/16	CI
Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.	08/16/08	CI
Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership	06/16/06	CI
Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.	21/16/21	CI
Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.	16/16/16	CI
American Home Alliance Corp will Change its Ticker to EMBT from AHLL	24/16/24	CI
AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc	24/16/24	CI
Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.	03/16/03	CI
Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7	20/15/20	CI
Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.	12/15/12	CI
Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.	31/14/31	CI
Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid	27/12/27	CI
Ember Therapeutics, Inc. Announces Management Appointments	30/12/30	CI
Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center	31/12/31	CI

Press releases Ember Therapeutics, Inc.

Alternative Liquidity Index LP Announces an Extension of the Tender Offer for Ember Therapeutics, Inc.

29/22/29

AQ

More press releases

Highs and lows

1 year

0.00

0.00

3 years

0.00

0.40

5 years

0.00

9.99

10 years

0.00

9.99

Managers and Directors - Ember Therapeutics, Inc.

Managers	Title	Age	Since
Hyun D. Kim PRN	Corporate Officer/Principal	-	-

Company Profile

Sector

-

More about the company

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW